Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €55.50 EUR
Change Today +2.85 / 5.41%
Volume 0.0
8AK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (8AK) Snapshot

Open
€52.79
Previous Close
€52.65
Day High
€55.50
Day Low
€52.75
52 Week High
03/5/15 - €67.90
52 Week Low
10/13/14 - €30.36
Market Cap
8.3B
Average Volume 10 Days
105.7
EPS TTM
€-0.90
Shares Outstanding
149.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALKERMES PLC (8AK)

alkermes plc (8AK) Related Businessweek News

View More BusinessWeek News

alkermes plc (8AK) Details

Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.

1,300 Employees
Last Reported Date: 02/24/15
Founded in 1987

alkermes plc (8AK) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $854.7K
President
Total Annual Compensation: $630.6K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $468.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $468.1K
Chief Compliance Officer, Chief Legal Officer...
Total Annual Compensation: $459.4K
Compensation as of Fiscal Year 2014.

alkermes plc (8AK) Key Developments

Alkermes Provides Update on FDA Review of ARISTADA for the Treatment of Schizophrenia

Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has advised Alkermes that it will not be able to complete its review of the New Drug Application (NDA) for ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia by the Prescription Drug User Fee Act (PDUFA) action date of Aug. 22, 2015. The FDA indicated that this delay was expected to be brief, measured in terms of weeks, but could not confirm specific timing. The FDA also indicated that no additional data or information is required from Alkermes at this time.

Alkermes plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Alkermes plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $151,370,000 against $153,424,000 a year ago. Operating loss was $52,521,000 against $22,825,000 a year ago. Loss before income taxes was $43,045,000 against income before income taxes of $2,212,000 a year ago. Net loss was $46,109,000 against net income of $3,735,000 a year ago. Basic and diluted GAAP loss per share was $0.31 against basic and diluted non-gaap earnings of $0.02 a year ago. Basic and diluted non-gaap loss per share was $0.09 against diluted earnings per share of $0.11 a year ago. Non-GAAP net loss was $13,585,000 against non-GAAP net income of $17,722,000 a year ago. Capital expenditures were $14,046,000 against $5,753,000 a year ago. Free cash outflow was $27,631,000 against free cash inflow of $11,969,000 a year ago. For the six months, the company reported total revenues of $312,584,000 against $283,636,000 a year ago. Operating loss was $79,829,000 against $38,718,000 a year ago. Loss before income taxes was $73,192,000 against $18,376,000 a year ago. Net loss was $76,766,000 against $20,619,000 a year ago. Basic and diluted GAAP loss per share was $0.52 against $0.14 a year ago. Basic and diluted non-gaap loss per share was $0.03 against $0.22 a year ago. Non-GAAP net loss was $13,585,000 against non-GAAP net income of $17,722,000 a year ago. Capital expenditures were $14,046,000 against $5,753,000 a year ago. Free cash outflow was $27,631,000 against free cash inflow of $11,969,000 a year ago. Non-GAAP net loss was $4,428,000 against non-GAAP net income of $33,873,000 a year ago. Capital expenditures were $24,756,000 against $11,438,000 a year ago. Free cash outflow was $29,184,000 against free cash inflow of $22,435,000 a year ago. For the year 2015, the company expects net loss of $257.5 million or $1.72 net loss per share. Deferred revenue is expected to be $3.0 million. Projected non-gaap net loss is expected to be $57.0 million or $0.38 loss per share. Capital expenditures were expected to be $50.0 million. Projected free cash outflow is expected to be $107.0 million.

Alkermes plc to Report Q2, 2015 Results on Jul 30, 2015

Alkermes plc announced that they will report Q2, 2015 results at 8:30 AM, Eastern Daylight on Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €55.50 EUR +2.85

8AK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $28.38 USD -0.42
Emergent BioSolutions Inc $34.64 USD +0.36
Impax Laboratories Inc $42.40 USD -1.57
Jazz Pharmaceuticals PLC $172.82 USD +2.05
Lupin Ltd 1,861 INR -39.00
View Industry Companies
 

Industry Analysis

8AK

Industry Average

Valuation 8AK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.